# Omeros Posts $35.9 Million Q3 Revenue, Below FactSet Estimate, and Swings to Adjusted Earnings

> Omeros reported $35.9 million in third-quarter revenue, short of the $37.3 million FactSet estimate, while swinging to adjusted earnings and lifting YARTEMLEA sales 26%.

- Published: 2026-11-16T22:03:10+00:00
- Section: Earnings & Results
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-16/omeros-q3-revenue-adjusted-earnings
- Source: [MarketScreener](https://www.marketscreener.com/news/omeros-q3-swings-to-adjusted-earnings-ce785edfdc89fe20)

## Key takeaways

- Omeros reported third-quarter revenue of $35.9 million, missing the FactSet estimate of $37.3 million.
- YARTEMLEA net revenue rose 26% to $35.9 million in the quarter.
- Omeros recorded a GAAP net loss of $57.4 million, or $0.79 per share, including a $62.0 million non-cash derivative remeasurement charge.

[Omeros](https://akta.pro/company-profiles/0000wi3/omeros) reported third-quarter revenue of $35.9 million, missing the FactSet estimate of $37.3 million, and swung to adjusted earnings, [MarketScreener](https://www.marketscreener.com/news/omeros-q3-swings-to-adjusted-earnings-ce785edfdc89fe20) reported on November 16, 2026. The company's stock closed at $16.68, down 4.63% from the prior close.

## Omeros Swings to Adjusted Profit as YARTEMLEA Sales Climb

Omeros is a commercial-stage biopharmaceutical company that develops therapies for complement-mediated diseases, central nervous system disorders and oncology, and sells YARTEMLEA, which it describes as the only FDA-approved therapy for TA-TMA, according to company records.

YARTEMLEA net revenue rose 26% to $35.9 million in the quarter, TradingView reported. Omeros posted a GAAP net loss of $57.4 million, or $0.79 per share, which included a $62.0 million non-cash derivative remeasurement charge. Operating cash flow was $13.3 million, and the company held $95.3 million in cash and short-term investments.

MarketScreener reported that Omeros swung to adjusted earnings in the quarter and did not disclose further details on the adjusted figure.

## YARTEMLEA Billing and Launch Figures

Omeros launched YARTEMLEA commercially in the US on January 2, 2026, and reached cash-flow positivity in the first quarter of 2026 with 30 accounts ordering product and $9.89 million in first-quarter sales, according to akta.pro [company records](https://akta.pro/company-data). CMS assigned a permanent HCPCS J-code, J1289, for YARTEMLEA effective July 1, 2026, which the records describe as streamlining Medicare and commercial payer billing and reimbursement at the $36,000 per-vial price point.

## EMA Opinions and a Securities Investigation

Pomerantz LLP is investigating Omeros for potential securities fraud following two European Medicines Agency negative opinions on its narsoplimab marketing authorisation application, GlobeNewswire reported. The stock fell 19.12% to $8.67 after the first negative opinion and 13.78% to $16.20 after a re-examination.

Omeros announced on November 10, 2026, that it would report third-quarter results after market close on November 16 and host a conference call and webcast at 4:30 p.m. Eastern Time, FinancialContent Business Page reported.

## Omeros Pipeline Timeline

Omeros said its OncotoX-AML cancer therapeutic platform achieved up to 99% reduction in myeloid progenitor cells in nonhuman primate studies and is advancing to IND-enabling studies, with a first-in-human trial targeted for late 2027, according to [its announcement](http://www.omeros.com).

## Companies in this story

- [Omeros company profile](https://akta.pro/company-profiles/0000wi3/omeros) · website: http://www.omeros.com

---
News for Agent · https://newsforagent.com/llms.txt
